Assembly Biosciences Reported Positive Phase 1a Results

The company's drug candidate ABI-6250 was well tolerated in a recent clinical trial for healthy participants.

Updated on Oct. 5, 2026 in Biotech

Isometric editorial illustration showing a row of glass laboratory vials on a steel surface, symbolizing pharmaceutical clinical trial research. — Assembly Biosciences announced positive results from its Phase 1a clinical trial of ABI-6250, a potential treatment for chronic liver diseases. AI Illustration. Upload story photo >

Live Poll

Do you trust that pharmaceutical companies prioritize patient safety during the clinical testing of new drugs?

Assembly Biosciences has completed a randomized, blinded Phase 1a study of its drug candidate ABI-6250. The treatment demonstrated dose-dependent, reversible increases in bile acids and was found to be well tolerated by healthy participants.

Why it matters

The study successfully assessed the safety, tolerability, and pharmacodynamic properties of ABI-6250. These results represent a key milestone in the development of a potential treatment for chronic HDV and cholestatic liver diseases.

The study demonstrated that ABI-6250 inhibits the sodium taurocholate co-transporting polypeptide in hepatocytes to block bile acid uptake. The pharmacodynamic findings were officially recognized as a Poster of Distinction.

The players

Assembly Biosciences

A biotechnology company based in South San Francisco that focuses on developing treatments for serious liver diseases.

The details

The drug candidate inhibits bile acid uptake into liver cells by blocking the sodium taurocholate co-transporting polypeptide. Findings from the study will be showcased in two separate posters at the upcoming medical conference.

November 5-9, 2026: The Liver Meeting 2026 occurs in Denver.
November 7, 2026: Presentation of the Phase 1a study data.
Q4 2026: Planned start of Phase 2 studies for HDV.
Q1 2027: Planned start of Phase 2 studies for cholestatic liver diseases.

The Big Picture

The presentation of clinical trial data at The Liver Meeting 2026 serves as the primary forum for updating the scientific community on hepatology advancements. This announcement follows the established pattern of clinical development milestones presented at this international research gathering.

While the drug is currently in early-stage development, success in future clinical phases could lead to new treatment options for patients managing chronic liver conditions. The current data indicates a strong safety profile for the candidate as it moves toward larger human trials.

The takeaway

The successful completion of this early trial allows the manufacturer to proceed with larger human studies scheduled for 2026 and 2027. Researchers will continue to monitor the drug's performance to validate its potential as a long-term therapeutic solution.

What happens next

Assembly Biosciences plans to initiate Phase 2 clinical studies for chronic HDV infection in the fourth quarter of 2026, followed by trials for cholestatic liver diseases in the first quarter of 2027.